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between B16 melanoma and Mφs. These hybrids retained nuclear
IRF3 translocation but failed to express IFN-β indicating a dominant-
negative mechanism. Sequencing revealed no mutations in the IFN-β
promoter. However, ATAC-sequencing indicated the IFN-β promoter
remained epigenetically closed after STING pathway activation in B16
tumor cells, unlike Mφ controls. NF-κB is an innate immune pathway
proposed to control IFN-β locus accessibility. We found B16 tumor
cells and hybrids were defective in NF-κB nuclear translocation, un-
like Mφ controls. Furthermore, tumor cells expressed normal levels of
most NF-κB factors but over expressed the negative regulator IκBα.
Combined treatment with cycloheximide and a STING agonist caused
IκBα degradation and tumor cell-intrinsic IFN-β expression.
Conclusions
We find tumor cells fail to express IFN-β downstream of STING path-
way activation. This is likely due to a dominant-negative inhibitor of
NF-κB signaling, such as IκBα, which causes the IFN-β locus to remain
epigenetically repressed in tumor cells and prevents IRF3 binding.
We hypothesize restoring NF-κB signaling in tumor cells will enable
tumor cell-intrinsic IFN-β expression and promote tumor rejection
in vivo. Therapies based on identifying and reversing tumor-specific
defects in IFN-β expression represent a strategy to induce tumor site-
specific innate immune activation.
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Background
NF-κB is a key regulator of inflammation, myeloproliferation and can-
cer progression, with an important role in leukemogenesis. Despite
therapeutic potential, targeting NF-κB proved challenging. However,
in non-malignant myeloid cells NF-κB activity is tightly regulated
through many molecular mechanisms, including miRNA.
Methods
Here, we describe an original approach to NF-κB inhibition using
miR146a, which targets upstream regulators of NF-κB signaling. We
generated a myeloid cell-targeted NF-κB inhibitor by tethering a
chemically-modified miR146a mimic oligonucleotide to a scavenger
receptor (SR)/Toll-like receptor 9 (TLR9) ligand (C-miR146a).
Results
Unlike an unconjugated miR-146a molecule, C-miR146a was rapidly
internalized and delivered to cytoplasm of target myeloid cells such
as macrophages or myeloid leukemia cells. C-miR146a reduced pro-
tein levels of classic miR-146a targets, IRAK1 and TRAF6, thereby effi-
ciently blocking NF-κB activation in target cells. Intravenous
injections of C-miR146a mimic to miR-146-deficient mice prevented
excessive NF-κB activation in myeloid cells, thereby alleviating myelo-
proliferation and exaggerated inflammatory responses to bacterial
challenge. The NF-κB-driven release of IL-1 and IL-6 from monocytes
is known to be responsible for cytokine release syndrome (CRS),
which can occur in response to bacterial infections, antibody-based
therapies and relatively frequently as a serious adverse effect of
chimeric antigen receptor (CAR) T-cell therapies. While low expres-
sion of miR146a has not yet been implicated in CRS, C-miR146a treat-
ments did reduce pro-inflammatory activity of human monocytes, at
the level of IL-1 and IL-6 production, induced by the CD19-specific
but not by the naive CAR T cells in vitro. Repeated systemic adminis-
tration of C-miR146a oligonucleotide alleviated human monocyte-
dependent CRS in xenotransplanted B-cell lymphoma model without
impeding the on-target therapeutic effects of CAR T-cells against
lymphoma cells.
Conclusions
Our results demonstrate potential of using myeloid cell-targeted
miR146a mimics for treatment of inflammatory diseases and preven-
tion of potential side effects of immunotherapies. The SR/TLR9-tar-
geted miR-146a mimic design provides an outline for the
development of miRNA therapeutics for a variety of myeloid cell-
related diseases.
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Background
Allogeneic NK cell infusions can achieve remission in 30-50% of pa-
tients with relapsed/refractory acute myeloid leukemia (AML). This
strategy may be limited by NK cell heterogeneity and lack of specifi-
city. NK cells mediate antibody-dependent cellular cytotoxicity of tu-
mors coated with therapeutic antibodies through the CD16 receptor.
While a strong activation receptor, CD16 is also present on neutro-
phils, which represent a sink for CD16-driven therapies. To bypass
this issue, we elected to target NKG2C, an activating receptor with
better specificity which is present on more differentiated NK cells.
CD94/NKG2C is a heterodimeric receptor that binds to HLA-E and as-
sociates with DAP12. NKG2C+ cells are enriched in AML patients who
have undergone a hematopoietic stem cell transplant and reacti-
vated CMV. [1] NKG2C+ NK cells are more responsive to AML and pa-
tients with higher circulating NKG2C+ cells have improved relapse
free survival. [2]
Methods
We aimed to direct specific killing and proliferation of the NKG2C+
cells using a NKG2C1533 Tri-specific Killer Engager (TriKE), containing
single chain variable fragments specific for NKG2C (on NK cells) and
CD33 (on AML cells), and an IL15 moiety (to support NK cell survival
and proliferation). An obstacle to utilizing NKG2C is the frequency of
NKG2C+ cells, so we genetically modified induced pluripotent stem
cells (iPSCs) to stably overexpress NKG2C alone or along with DAP12.
We then differentiated these cells to NK (iNK) cells.
Results
In the presence of AML cell lines, NKG2C1533 TriKE activated NK cells
from transplant patients with CMV reactivation, where NKG2C+ fre-
quency correlated with activation (Figure 1A,B). The NKG2C1533
TriKE also led to preferential expansion of NKG2C+ cells (Figure 1C).
We found that the NKG2C1533 TriKE mediated robust activation of
NKG2C iNK cells and NKG2C/DAP12 iNK cells leading to THP1 cell kill-
ing (Figure 1D). The NKG2C/DAP12 iNKs exhibited the strongest
response.
Conclusions
Engaging NK cells through NKG2C or genetically modified iNK cells
expressing NKG2C, will be more specific than targeting through
CD16, which will bind to CD16A on NK cells but also have off-target
binding to CD16B on neutrophils. The NKG2C1533 TriKE is an effect-
ive way to selectively target NK cells with two applications, one in in-
dividuals with high frequencies of NKG2C+ cells and another within
the iNK cell platform creating an “off-the-shelf” NK cellular therapy
that is targeted, specific and efficacious where TriKE can be co-
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